Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMENSL5)

Drug Name
Aminosalicylic Acid Drug Info
Synonyms
4-Aminosalicylic acid; 65-49-6; Aminosalicylic acid; P-AMINOSALICYLIC ACID; Rezipas; Aminopar; Pamisyl; Parasalindon; Ferrosan; Deapasil; Apacil; Parasal; Paser; Paramycin; Gabbropas; Parasalicil; Pasnodia; Osacyl; Aminox; Pasolac; Pasmed; Propasa; Pasalon; Entepas; Pasdium; Pasara; Pamacyl; Pasem; Pasa; 2-Hydroxy-4-aminobenzoic acid; PASK; APAS; Para-Pas; Sanipirol-4; Hellipidyl; Pascorbic; PAS-C; Benzoic acid, 4-amino-2-hydroxy-; PAS (acid); Aminosalicylic Acid Resin Complex; Aminosalicylate Sodium
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Inflammatory bowel disease DD72 Approved [2]
Pulmonary and extrapulmonary tuberculosis 1B10.Z Approved [2]
Pulmonary tuberculosis 1B10.Z Approved [1]
Ulcerative colitis DD71 Approved [1]
Cross-matching ID
PubChem CID
4649
ChEBI ID
CHEBI:27565
CAS Number
CAS 65-49-6
TTD Drug ID
DMENSL5
VARIDT Drug ID
DR01160
INTEDE Drug ID
DR1748

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dihydrofolate reductase (DHFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trimethoprim DMM7CHK Acute otitis media AB00 Approved [3]
Leucovorin Calcium DMNWZJG Solid tumour/cancer 2A00-2F9Z Approved [8]
Methotrexate Sodium DM5XH2C Solid tumour/cancer 2A00-2F9Z Approved [3]
Iclaprim DM7YNV9 Bacterial infection 1A00-1C4Z Phase 3 [9]
PIRITREXIM DM276N1 Bladder cancer 2C94 Phase 2 [10]
CH-4051 DMLQRYH Rheumatoid arthritis FA20 Phase 2 [11]
MDAM (y-methylene-10-deazaaminopterin) DM1DISM Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
L-MDAM DMU901D Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
VYR 006 DMC9N7D Toxoplasmosis 1F57 Phase 1 [14]
TNP-351 DMW05DS Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [16]
Naproxen DMZ5RGV Bursitis Approved [17]
Mesalazine DMOL5IU Diverticulitis Approved [18]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [19]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [20]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [21]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [3]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [22]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [23]
FENBUFEN DMXGDFK Arthritis FA20 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [25]
Naproxen DMZ5RGV Bursitis Approved [17]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [26]
Indomethacin DMSC4A7 Bursitis Approved [3]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [27]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [28]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [29]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [30]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [19]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic Acid DMEMBJC Colorectal carcinoma Approved [32]
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [33]
L-Alanine DMZDN4W Dietary shortage 5B5K Approved [33]
Drug(s) Metabolized By N-acetyltransferase 2 (NAT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [34]
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [35]
Hydralazine DMU8JGH Chronic heart failure BD1Z Approved [36]
Amifampridine DMK08L3 LambertEaton myasthenic syndrome 8C62 Approved [37]
Asacolitin DM3WVPJ N. A. N. A. Investigative [38]
Drug(s) Affected By Proepiregulin (EREG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [39]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [40]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [44]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Antileukoproteinase (SLPI)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [6]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [40]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [6]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [6]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hepatocyte growth factor receptor (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [46]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [47]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [48]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [49]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-8 (CXCL8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [50]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [51]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [52]
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [53]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [54]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [55]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [57]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [58]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [6]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [6]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [6]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [6]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [59]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [6]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-24 (IL24)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [6]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [55]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [6]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [62]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [43]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [63]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [6]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [63]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [6]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [6]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [6]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [6]
Amikacin DM5PDRB Bacteremia 1A73 Approved [6]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [6]
Promethazine DM6I5GR Hyperemesis gravidarum Approved [6]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [6]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [65]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [6]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [66]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [6]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [6]
Methotrexate DM2TEOL Anterior urethra cancer Approved [48]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [67]
Quercetin DM3NC4M Obesity 5B81 Approved [42]
Fluoxetine DM3PD2C Bipolar depression Approved [68]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Arylamine N-acetyltransferase 1 (NAT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Procainamide DMNMXR8 Ventricular arrhythmias BC71 Approved [69]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [70]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [71]
Methotrexate DM2TEOL Anterior urethra cancer Approved [69]
Testosterone DM7HUNW Hot flushes GA30 Approved [72]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [72]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [64]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [73]
Folic Acid DMEMBJC Colorectal carcinoma Approved [69]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [74]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dihydrofolate reductase (DHFR) TTYZVDJ DYR_HUMAN Modulator [3]
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Modulator [3]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium-coupled neutral amino acid transporter 3 (SLC38A3) DTKWJH3 S38A3_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
N-acetyltransferase 2 (NAT2) Main DME DER7TA0 ARY2_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [6]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Biotransformations [7]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [6]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Gene/Protein Processing [6]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Gene/Protein Processing [6]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Gene/Protein Processing [6]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Gene/Protein Processing [6]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Gene/Protein Processing [6]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Gene/Protein Processing [6]

References

1 Aminosalicylic acid FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
5 Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
6 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
7 Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005 Jan 15;69(2):347-59. doi: 10.1016/j.bcp.2004.09.014. Epub 2004 Nov 24.
8 Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
11 CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
12 Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
13 Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
14 Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.
15 A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974.
16 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
17 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
18 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
20 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
21 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
22 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
23 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
24 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
25 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
26 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
27 Pfizer. Product Development Pipeline. March 31 2009.
28 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
29 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
30 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
31 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
32 Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.
33 Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
34 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
35 Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
36 N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
37 Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
38 Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
39 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
40 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
41 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
42 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
43 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
44 Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
45 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
46 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
47 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
48 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
49 All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
50 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
51 Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
52 Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
53 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
54 Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
55 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
56 Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
57 Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
58 Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
59 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
60 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
61 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
62 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
63 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
64 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
65 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
66 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
67 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
68 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
69 Over-expression, purification, and characterization of recombinant human arylamine N-acetyltransferase 1. Protein J. 2005 Feb;24(2):65-77.
70 The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol. 2005 Apr;67(4):1299-306.
71 Sulindac inhibited gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in T24 human bladder tumor cells. Urol Res. 2001 Dec;29(6):406-11.
72 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
73 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
74 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.